ARTICLE | Clinical News

Opdivo: Ph III ONO-4538-12 data

November 11, 2016 8:54 PM UTC

The double-blind, Asian Phase III ONO-4538-12 trial in about 480 patients with unresectable advanced or recurrent gastric cancer refractory to or intolerant of standard therapy showed that 3 mg/kg IV Opdivo every 2 weeks met the primary endpoint of improving OS vs. placebo. Bristol-Myers declined to provide a timeline for submitting regulatory applications for Opdivo to treat gastric cancer. Ono conducted the trial...